2020
Predicting outcomes following second intent healing of periocular surgical defects
Kibbi N, Khan Y, Leffell DJ, Christensen SR, Suozzi KC. Predicting outcomes following second intent healing of periocular surgical defects. Archives Of Dermatological Research 2020, 313: 483-489. PMID: 32833078, DOI: 10.1007/s00403-020-02122-w.Peer-Reviewed Original ResearchConceptsMohs micrographic surgeryMedial canthusSingle academic surgical centerAcademic surgical centerConclusionsThis retrospective studyMedial canthal lesionAverage defect diameterMethodsRetrospective analysisTumor characteristicsPeriocular tumorsRetrospective studyPoor outcomePeriocular lesionsSurgical centersMicrographic surgeryWorse outcomesAnatomic locationAimThe purposeScar outcomeLarge lesionsUpper eyelidEyelid marginLid marginSurgical defectsLower eyelid
2019
Photodynamic therapy for cutaneous squamous cell carcinoma in situ: Impact of anatomic location, tumor diameter, and incubation time on effectiveness
Kibbi N, Zhang Y, Leffell DJ, Christensen SR. Photodynamic therapy for cutaneous squamous cell carcinoma in situ: Impact of anatomic location, tumor diameter, and incubation time on effectiveness. Journal Of The American Academy Of Dermatology 2019, 82: 1124-1130. PMID: 31712171, DOI: 10.1016/j.jaad.2019.10.079.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAminolevulinic AcidAnalysis of VarianceBiopsy, NeedleCarcinoma in SituCarcinoma, Squamous CellCohort StudiesDisease-Free SurvivalFemaleHumansImmunohistochemistryLogistic ModelsMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingPhotochemotherapyPrognosisRetrospective StudiesSkin NeoplasmsSurvival AnalysisTreatment OutcomeTumor BurdenConceptsCutaneous squamous cell carcinomaALA incubation timeSquamous cell carcinomaTumor diameterALA-PDTSubsequent recurrenceCell carcinomaAnatomic locationInitial complete response ratePhotodynamic therapyCases of SCCISMultivariate analysis factorsComplete response rateMedical record reviewEffectiveness of PDTPatient demographicsClinical responseMedian timeRetrospective reviewRecord reviewRetrospective studyTreatment detailsSingle institutionEffective treatmentResponse rateComparison of Survival After Mohs Micrographic Surgery vs Wide Margin Excision for Early-Stage Invasive Melanoma
Cheraghlou S, Christensen SR, Agogo GO, Girardi M. Comparison of Survival After Mohs Micrographic Surgery vs Wide Margin Excision for Early-Stage Invasive Melanoma. JAMA Dermatology 2019, 155: 1252-1259. PMID: 31553403, PMCID: PMC6764120, DOI: 10.1001/jamadermatol.2019.2890.Peer-Reviewed Original ResearchWide margin excisionMohs micrographic surgeryNational Cancer DatabaseOverall survivalInvasive melanomaStage IMargin excisionCancer DatabaseMicrographic surgeryCox proportional hazards regression survival analysisCox proportional hazards regression analysisCancer (AJCC) Cancer Staging ManualUse of MMSPropensity score-matched analysisProportional hazards regression analysisCancer-accredited facilitiesRetrospective cohort studyAmerican Joint CommitteeCancer Staging ManualHazards regression analysisCommon malignant neoplasmTreatment of melanomaRegression survival analysisComparison of survivalEligible patientsRepairs of the Ear
Christensen S, Stamey C. Repairs of the Ear. 2019, 499-521. DOI: 10.1007/978-3-030-02023-1_31.ChaptersUnique reconstructive challengeHigh-level evidenceEvidence-based reviewAuricular reconstructionPrimary repairCosmetic outcomeSkin graftsSurgical reconstructionReconstructive challengeSurgical defectsSecond intentionExternal earRepair typeCosmetic requirementsEarRepairFlapAuricleMajor categoriesOutcomesViable optionGraftStrong evidence
2018
Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas
Christensen SR. Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas. F1000Research 2018, 7: f1000 faculty rev-690. PMID: 29904586, PMCID: PMC5989149, DOI: 10.12688/f1000research.12837.1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSquamous cell carcinomaMultiple squamous cell carcinomasCutaneous squamous cell carcinomaField cancerizationPrecursor lesionsCell carcinomaMultiple cutaneous squamous cell carcinomasIncident squamous cell carcinomaSubsequent squamous cell carcinomaField-directed therapySevere actinic damageTopical ingenol mebutateMultiple primary cancersManagement of patientsSubsequent cancer developmentSystemic acitretinTopical imiquimodPrimary cancerCommon cancerMultiple tumorsIngenol mebutateSCC developmentActinic damageField therapyPatients
2017
Sirolimus-Associated Rapid Progression of Leg Ulcers in a Renal Transplant Recipient
Totonchy MB, Colegio OR, Christensen SR. Sirolimus-Associated Rapid Progression of Leg Ulcers in a Renal Transplant Recipient. JAMA Dermatology 2017, 153: 105-106. PMID: 27806175, DOI: 10.1001/jamadermatol.2016.3546.Peer-Reviewed Original Research
2015
Histopathologic assessment of depth of follicular invasion of squamous cell carcinoma (SCC) in situ (SCCis): Implications for treatment approach
Christensen SR, McNiff JM, Cool AJ, Aasi SZ, Hanlon AM, Leffell DJ. Histopathologic assessment of depth of follicular invasion of squamous cell carcinoma (SCC) in situ (SCCis): Implications for treatment approach. Journal Of The American Academy Of Dermatology 2015, 74: 356-362. PMID: 26670714, DOI: 10.1016/j.jaad.2015.09.060.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaHair follicle infundibulumFollicular invasionCell carcinomaMohs micrographic surgeryHair follicle epitheliumAdditional patientsIntraoperative pathologyOptimal therapyRetrospective reviewTreatment failureProspective evaluationSingle institutionHistopathologic assessmentMicrographic surgeryMost tumorsDeep invasionTreatment approachesPathology specimensFollicle epitheliumLower follicleSCCISSurgeryCarcinomaInvasion
2014
Cancer of the Skin
Christensen, S.R., and Leffell, D.J. in Cancer: Principles and Practice of Oncology, 10th Edition, Lippincott Williams &Wilkins.Chapters
2013
TLR9 Promotes Tolerance by Restricting Survival of Anergic Anti-DNA B Cells, Yet Is Also Required for Their Activation
Nickerson KM, Christensen SR, Cullen JL, Meng W, Prak E, Shlomchik MJ. TLR9 Promotes Tolerance by Restricting Survival of Anergic Anti-DNA B Cells, Yet Is Also Required for Their Activation. The Journal Of Immunology 2013, 190: 1447-1456. PMID: 23296704, PMCID: PMC3563726, DOI: 10.4049/jimmunol.1202115.Peer-Reviewed Original ResearchConceptsAnti-DNA B cellsB cellsBone marrowAbsence of TLR9Autoimmune prone animalsAutoimmune-prone MRLSystemic lupus erythematosusAnergic B cellsB cell compartmentB cell toleranceAb-forming cellsL chain editingB cell life spanFunctional anergyLupus erythematosusTLR9 expressionAutoreactive cellsPeripheral activationExtrafollicular pathwayPeripheral repertoireSystemic autoimmunityMouse modelAnergic cellsTLR9Cell life span
2011
Preoperative Evaluation
Christensen S, Aasi S. Preoperative Evaluation. 2011, 13-33. DOI: 10.1007/978-1-4471-2152-7_3.ChaptersPreoperative evaluationPresenting lesionsPerioperative periodCardiac conditionsRecent American Heart Association guidelinesDermatologic surgeryAmerican Heart Association guidelinesPatient's unique historyHeart Association guidelinesPast medical historyHigh-quality surgical outcomesFatal thrombotic complicationsImplantable cardiac defibrillatorMedical history formCardiac medicationsPreoperative antibioticsProphylactic antibioticsCurrent medicationsThrombotic complicationsCutaneous sitesSurgical outcomesMedical historyAssociation guidelinesOral mucosaHigh risk
2009
RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes
Avalos AM, Kiefer K, Tian J, Christensen S, Shlomchik M, Coyle AJ, Marshak-Rothstein A. RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. Autoimmunity 2009, 43: 103-110. PMID: 20014975, PMCID: PMC2929824, DOI: 10.3109/08916930903384591.Peer-Reviewed Original ResearchConceptsAM14 B cellsB cell activationHMGB1-DNA complexHMGB1-RAGE interactionNuclear DNACell activationAutoreactive B cell activationB cell responsesB cellsDNA immune complexesImmune complexesSoluble formRole of HMGB1DNAAutoreactive B cell responsesCell responsesCell debrisCellsCellular debrisExcessive accumulationRAGE-deficient miceSystemic autoimmune diseaseActivationRole of RAGETLR9-dependent mannerDifferential Cytokine Production and Bystander Activation of Autoreactive B Cells in Response to CpG-A and CpG-B Oligonucleotides
Avalos AM, Latz E, Mousseau B, Christensen SR, Shlomchik MJ, Lund F, Marshak-Rothstein A. Differential Cytokine Production and Bystander Activation of Autoreactive B Cells in Response to CpG-A and CpG-B Oligonucleotides. The Journal Of Immunology 2009, 183: 6262-6268. PMID: 19864612, PMCID: PMC3426913, DOI: 10.4049/jimmunol.0901941.Peer-Reviewed Original ResearchMurine B Cell Response to TLR7 Ligands Depends on an IFN-β Feedback Loop
Green NM, Laws A, Kiefer K, Busconi L, Kim YM, Brinkmann MM, Trail EH, Yasuda K, Christensen SR, Shlomchik MJ, Vogel S, Connor JH, Ploegh H, Eilat D, Rifkin IR, van Seventer JM, Marshak-Rothstein A. Murine B Cell Response to TLR7 Ligands Depends on an IFN-β Feedback Loop. The Journal Of Immunology 2009, 183: 1569-1576. PMID: 19587008, PMCID: PMC2929820, DOI: 10.4049/jimmunol.0803899.Peer-Reviewed Original Research
2008
Autoreactive B Cells Discriminate CpG-Rich and CpG-Poor DNA and This Response Is Modulated by IFN-α
Uccellini MB, Busconi L, Green NM, Busto P, Christensen SR, Shlomchik MJ, Marshak-Rothstein A, Viglianti GA. Autoreactive B Cells Discriminate CpG-Rich and CpG-Poor DNA and This Response Is Modulated by IFN-α. The Journal Of Immunology 2008, 181: 5875-5884. PMID: 18941176, PMCID: PMC2584609, DOI: 10.4049/jimmunol.181.9.5875.Peer-Reviewed Original ResearchConceptsAutoreactive B cellsDNA-reactive B cellsB cellsImmune complexesIFN-alphaLow-affinity autoreactive B cellsSystemic lupus erythematosusB cell proliferationBCR transgenic miceTLR9-dependent activationLupus erythematosusUnmethylated CpG dinucleotideTransgenic miceImmunostimulatory motifsCell proliferationActivation thresholdTLR9Normal repertoireCellsPotent ligandsBCRCpG island fragmentsDual engagementActivationImportant mechanism
2007
Bazex syndrome (acrokeratosis paraneoplastica)
Poligone B, Christensen SR, Lazova R, Heald PW. Bazex syndrome (acrokeratosis paraneoplastica). The Lancet 2007, 369: 530. PMID: 17292773, DOI: 10.1016/s0140-6736(07)60240-2.Peer-Reviewed Original Research
2006
Toll-like Receptor 7 and TLR9 Dictate Autoantibody Specificity and Have Opposing Inflammatory and Regulatory Roles in a Murine Model of Lupus
Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like Receptor 7 and TLR9 Dictate Autoantibody Specificity and Have Opposing Inflammatory and Regulatory Roles in a Murine Model of Lupus. Immunity 2006, 25: 417-428. PMID: 16973389, DOI: 10.1016/j.immuni.2006.07.013.Peer-Reviewed Original ResearchConceptsLupus-prone miceSystemic lupus erythematosusAutoimmune diseasesToll-like receptor 7Toll-like receptor 9Absence of TLR9TLR7-deficient miceDevelopment of lupusPlasmacytoid DCsLupus erythematosusSerum IgGSusceptible miceAutoantibody specificitiesReceptor 7Receptor 9DNA autoantibodiesClinical diseaseIFN-alphaMurine modelLymphocyte activationTLR7TLR9Regulatory roleDiseaseMice
2005
Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus
Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. Journal Of Experimental Medicine 2005, 202: 321-331. PMID: 16027240, PMCID: PMC2212997, DOI: 10.1084/jem.20050338.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, AntinuclearAntibody FormationAutoantigensAutoimmunityB-LymphocytesDNADNA-Binding ProteinsHumansImmunity, InnateLupus NephritisMembrane GlycoproteinsMiceMice, KnockoutReceptors, Cell SurfaceRibonucleoproteins, Small NuclearSnRNP Core ProteinsToll-Like Receptor 3Toll-Like Receptor 9Toll-Like ReceptorsConceptsToll-like receptor 9TLR9-deficient miceAutoantibody productionAutoimmune diseasesReceptor 9Clinical autoimmune diseaseDNA-containing antigensSelf-nuclear antigensAnti-DNA autoantibody productionAnti-dsDNA autoantibodiesLupus-prone miceSystemic lupus erythematosusFormation of autoantibodiesSystemic autoimmune diseaseInnate immune activationAutoreactive B cellsLupus erythematosusAutoantibody formationMurine lupusImmune activationImmunologic toleranceAntichromatin autoantibodiesSmith antigenCpG DNAB cells